NEWS

WIRES

OTHER

Micromedex 2.0 Now Available for Web and Mobile Access

Micromedex 2.0 gives clinicians direct web and mobile access to Micromedex content through a new user interface that combines enhanced search with user-based interface design to simplify and enhance the way they use referential information.

Pharmacists, nurses, and physicians in more than 3,500 hospitals in 83 countries use Micromedex for evidence-based information on drugs, disease management, toxicology, neonatal dosing, and alternative medicines as well as patient education material. Micromedex 2.0 was designed to help clinicians make better use of this wealth of information. New features include an interface based on clinician workflow patterns, enhanced search capabilities, special tabs for high-usage tools, and compatibility with iPhone®, iPod® Touch, BlackBerry® smartphones, and other mobile devices.

New search functionality allows for multi-term search, predictive text, synonyms and suggestions for alternate spellings. The new single search box on every page means users won't have to return to the home page to start a search. Highly used features -- such as dosing calculators, Trissel's (TM)2 IV compatibility, drug identification, and drug interaction checking -- have been pulled into separate tabs so they can be accessed and used quickly.

Micromedex 2.0 also simplifies how clinicians see results. The new 360-degree view of results provides a complete picture of all available information about a drug or condition on a single screen -- including drug summaries, images, consults, comparative efficacy information, labeled and off-label indications, treatment options, and more. As a result, clinicians get directly to the information they need with a minimum of effort.

"Some of our pharmacists were worried about having to learn a new system," said Arpi Kuyumjian, clinical coordinator at Hackensack University Medical Center. "But once they used Micromedex 2.0 and saw how they get everything they need on a single screen they really liked it."

Micromedex 2.0 also supports mobile access on the newest devices. With optimized browser performance for the Safari and Opera Mini browsers, clinicians can access the full Micromedex content via their iPhone, iTouch, BlackBerry smartphone, and other high-speed enabled phones and devices. "We're very excited about the mobile capability," said Kuyumjian. "Our staff will definitely appreciate it because so much is done on their phones."

Micromedex 2.0 is available at no additional charge for existing Micromedex customers. For more information, visit www.micromedex.com/2. Customers wishing to transition to Micromedex 2.0 should contact customer support at 1-877-843-6796 and say "Micromedex."

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE: TRI). For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters